Potential side effects of osimertinib?
This website is only intended for UK patients who have been prescribed TAGRISSO® (osimertinib)
Potential side effects of osimertinib?
Like all medicines, osimertinib has a list of known side effects, but not everybody gets them1
Each person’s reaction to cancer medication is different. Some people have few side effects while others may experience more.1,2
Two of the most common side effects –which happen in more than 1 in 10 patients – are diarrhoea and skin reactions such as redness around fingernails or acne-like rash. Most patients find these side effects mild to moderate in severity and manageable.1,3
Two of the most common side effects –which happen in more than 1 in 10 patients – are diarrhoea and skin reactions such as redness around fingernails or acne-like rash. Most patients find these side effects mild to moderate in severity and manageable.1,3
Other very common side effects are reduction in white blood cells (called leukocytes or neutrophils) and another type of blood cell called platelets. This may put you at increased risk of infection, and those infections are more likely to be severe or life-threatening; it may also affect how your blood clots. If you experience any symptoms of infection such as flu-like illness, or any unexplained bruising or bleeding, let your cancer care team know as soon as possible.Stomatitis, a condition that causes mouth sores, is another very common side effect which is explained in more detail on the ‘Safety Considerations’ page.1
Some serious side effects include interstitial lung disease and a heart condition called QT prolongation. You should tell your healthcare professional straight away if you feel breathless, dizzy or notice your heart beating in an abnormal way. Refer to the ‘Safety Considerations’ page for more information on these side effects. You should also tell your healthcare professional if you develop reddish circular patches with central blisters, called Steven-Johnson syndrome, or a skin reaction that appear like rings, called Target Lesions.1
You should also tell your healthcare professional if you develop watery eyes, sensitivity to light, eye pain or redness or vision changes.1
Very common side effects are dry skin, itching and skin rashes including acne-like rash. Other very common side effects are reduction in white blood cells (called leukocytes or neutrophils) and another type of blood cell called platelet which result into symptoms like persistent fever, bruising or bleeding more easily. If you are more tired than normal or are experiencing more infections or flu-like symptoms and pale skin, let your cancer care team know, as your blood count may be reduced. Stomatitis, a condition that causes inflammation of the inner lining of the mouth or ulcers forming in the mouth, is another very common side effect which is explained in more detail on the ‘Safety Considerations’ page.1
Some serious side effects include interstitial lung disease and a heart condition called QT Prolongation. You should tell your healthcare professional straight away if you experience difficulty in breathing with a cough or fever, have a fast or irregular heart beat, feel dizzy, faint or light-headed or experience shortness of breath.
You should tell your healthcare professional straight away if you feel breathless or dizzy or notice your ankles swelling or your heart beating in an abnormal way. Refer to the ‘Safety Considerations’ page for more information on these side effects.
You should also tell your healthcare professional if you develop reddish circular patches with central blisters, peeling skin, ulcers in the mouth, throat, nose, genitals or eyes called Steven-Johnson syndrome or a skin reaction that appear like rings, called Target Lesions.1
You should tell your doctor or healthcare professional if you previously have had a hepatitis B infection. This is because osimertinib could cause hepatitis B virus to become active again. Tell your doctor or nurse if you get worsening tiredness or yellowing of your skin or white part of your eyes.1
You should also tell your healthcare professional if you develop watery eyes, sensitivity to light, eye pain or redness or vision changes.1
Reporting the side effects of osimertinib
If you get any side effects, talk to your cancer care team. This includes any possible side effects not listed in the Patient Information Leaflet or mentioned on this website. You can also report side effects directly via the Yellow Card Scheme, website: http://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of medicines.
Side effects can also be reported to AstraZeneca in the following ways:
Online: https://contactazmedical.astrazeneca.com
Email: Medical.InformationUK@astrazeneca.com
For a full list of side effects please refer to the patient information leaflet that comes inside the package of your medicine.
Tell your healthcare professional or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines and medicines obtained without a prescription. This is because osimertinib can affect the way some other medicines work. Also some other medicines can affect the way osimertinib works.1
References:
- Tagrisso 40 mg and 80 mg film coated tablets. Patient Information Leaflet.
- American cancer society (ACS).Chemotherapy Side Effects. Available at: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html. Accessed December 2023.
- Tagrisso 40 mg and 80 mg film coated tablets. Summary of product characteristics.
GB-73013 I DOP: January 2026
This website is only intended for UK patients who have been prescribed TAGRISSO® (osimertinib), which is indicated after surgery in adults with stage 1B-3A NSCLC with a particular EGFR mutation, and also in locally advanced or metastatic NSCLC with a particular EGFR mutation. It does not replace the Patient Information Leaflet, which you can find in the carton containing your medicine and which you should read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.